Progyny reported record quarterly revenue and adjusted EBITDA for Q2 2026. Second quarter revenue rose 5.3% year-over-year, or 11% excluding contributions from a large former client under a transition agreement in Q2 2025. The fertility benefits provider's gross margin expanded 180 basis points year-over-year, driven by efficiencies in care management and service delivery. Operating cash flow reached more than $50 million for the fourth time in five quarters. Progyny repurchased nearly 1.2 million shares for $31.5 million during the quarter under its $200 million programme. Since November, the company has bought back 10.8 million shares, reducing shares outstanding by approximately 12.5%. The company projects full-year 2026 revenue between $1.36 billion and $1.385 billion, representing growth of 5.5% to 7.5%.

Progyny, Inc. to present at the Canaccord Genuity Annual Growth Conference. NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) - Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 3:30 p.m. ET. Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny's investor relations website at http://investors.progyny.com. About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain's Fast 50 for NYC. For more information, visit www.progyny.com. For Further Information, Please Contact: Investors: James Hart [email protected] Media: Alexis Ford [email protected] Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Fertility benefits company Progyny reported second-quarter results for 2026, with revenue of $350.5 million, beating analyst expectations by 0.6% and representing 5.3% year-on-year growth. The company's non-GAAP earnings per share of $0.55 also exceeded estimates by 6.2%. Despite the positive quarterly results, Progyny's stock dropped 10.2% following disappointing forward guidance. The company's revenue forecast for the next quarter of $340 million came in 3% below analyst estimates. Progyny also lowered its full-year revenue guidance to $1.37 billion from $1.39 billion, a 0.9% decrease. Chief Executive Officer Pete Anevski attributed the strong quarterly results to member engagement trending toward the higher end of expectations.